Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Maxim Group from a "strong-buy" rating to a "hold" rating.
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Brookline Capital Management from a "strong-buy" rating to a "hold" rating.
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
Quince Therapeutics (NASDAQ:QNCX) was downgraded by analysts at Lucid Cap Mkts from a "strong-buy" rating to a "strong sell" rating.